Keywords: enzon, gets, orphan, drug, status, new, version
Enzon gets Orphan Drug status for new version of Oncaspar
Article | 06 October 2008
New Jersey, USA-based Enzon Pharmaceuticals has received European Orphan Drug designation for its Oncaspar-IV (EZN-2285), a next-generation PEG- enhanced version ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
